View More Recent Stories
-
Nuvation Bio (NUVB) Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
-
Nuvation Bio executive Jerry Wang to depart after key milestones
-
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
-
Nuvation Bio (NUVB) Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
H.C. Wainwright Reiterates Buy Rating on Nuvation Bio Inc (NUVB)
-
Nuvation Bio (NUVB) Announces FDA Acceptance for Priority Review of New Drug Application for Taletrectinib
-
Clear Street Starts Nuvation Bio Inc (NUVB) at Buy
-
Nuvation Bio Inc. (NUVB) Misses Q3 EPS by 1c
-
Nuvation Bio (NUVB) Appoints Philippe Sauvage as CFO
-
Nuvation Bio Inc (NUVB) PT Lowered to $7 at H.C. Wainwright
-
Nuvation Bio Inc. (NUVB) Misses Q2 EPS by 183c
-
BTIG Reiterates Buy Rating on Nuvation Bio Inc (NUVB)

